Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma Journal Article

Authors: Herrera, A. F.; Moskowitz, A. J.; Bartlett, N. L.; Vose, J. M.; Ramchandren, R.; Feldman, T. A.; LaCasce, A. S.; Ansell, S. M.; Moskowitz, C. H.; Fenton, K.; Ogden, C. A.; Taft, D.; Zhang, Q.; Kato, K.; Campbell, M.; Advani, R. H.
Article Title: Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma
Abstract: In this phase 1/2 study, brentuximab vedotin (BV) and nivolumab (Nivo) administered in combination were evaluated as initial salvage therapy in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (HL). Patients received up to 4 cycles of combination treatment, with BV administered on day 1 and Nivo on day 8 of the first cycle. For cycles 2 to 4, BV and Nivo were both administered on day 1. After study treatment, responses were evaluated by investigators per the 2014 Lugano classification, and patients could proceed to autologous stem cell transplantation (ASCT). Sixty-two patients were enrolled; the complete response rate among all treated patients (n=61) was 61%, with an objective response rate of 82%. Before ASCT, adverse events (AEs) occurred in 98% of patients, mostly grades 1 and 2. Infusion-related reactions (IRRs) occurred in 44% of patients overall, with 41% of patients experiencing an IRR during at least 1 infusion of BV. Five patients (8%) were treated with systemic steroids for immune-related AEs. A reduction of peripheral T-cell subsets including regulatory T cells was observed after the first dose of BV, and reduced serum levels of thymus- and activation-regulated chemokine concurrent with an increase in proinflammatory cytokines and chemokines were seen after the first BV plus Nivo infusions. The combination of BV plus Nivo was an active and well-tolerated first salvage regimen, potentially providing patients with R/R HL an alternative to traditional chemotherapy.
Keywords: salvage therapy; chemotherapy; analysis; fdg-pet; trial; reveals; stem-cell transplantation; disease; high-dose; multicenter phase-ii; emission-tomography response; adapted therapy
Journal Title: Blood
Volume: 131
Issue: 11
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2018-03-15
Start Page: 1183
End Page: 1194
Language: English
ACCESSION: WOS:000430687500007
DOI: 10.1182/blood-2017-10-811224
PMCID: PMC5855021
PUBMED: 29229594
Notes: Article -- Source: Wos
Citation Impact
MSK Authors
  1. Craig Moskowitz
    388 Moskowitz
  2. Alison Moskowitz
    177 Moskowitz